Add to Calendar

Scientific Program

Print
Orient Foundation Museum
Thursday, March 17, 2016
CONy Opening session and Plenary Lectures 
Chairs: Amos D. Korczyn, Israel; Victor Oliveira, Portugal
Egas Moniz and his role in 20th century neurology
Victor Oliveira, Portugal
Hysteria, simulation and functional disorders: From Charcot to Charcot?
Julien Bogousslavsky, Switzerland
Can the brain be really understood?
Richard Frackowiak, Switzerland
Trinucleotide repeats
Sandra Macedonia-Ribeiro, Portugal
Shifting the paradigm in brain protection and recovery
Dafin Muresanu, Romania
Post-stroke cerebral reorganization
Jay P. Mohr, USA
Role of exosomes/miRNA in mediating recovery after stroke and traumatic brain injury?
Michael Chopp, USA
Redefining neurological diseases through epigenetics
Tiago Fleming Outeiro, Germany
Vagus nerve stimulation: Headachde and beyond
Stephen Silberstein, USA
Alzheimer's disease: Organelles or proteins?
Stavros Baloyannis, Greece
Can Alzheimer's disease be prevented?
Miia Kivipelto, Sweden
Debate : Is beta-amyloid still a relevant target in AD therapy?
Yes: Paulo Fontoura, Switzerland
No: Amos D. Korczyn, Israel
Welcome Reception

Friday, March 18, 2016
Multiple Sclerosis
Section Heads: Xavier Montalban, Spain & Olaf Stüve, USA
08:30-10:30 Session 1: MS I
08:30-09:30 Debate: Is NEDA a clinically relevant endpoint for therapeutic decisions?
09:30-10:30 Debate: My MRI worsened but I didn't. Should I change my disease-modifying treatment?
10:30-10:45 Coffee Break
10:45-12:45 Session 2: MS II
10:45-11:45 Debate: Is vitamin D a substantial disease modifier in patients with MS?
11:45-12:45 Debate: Placebo controlled treatment in NMO are unethical and not needed
12:45-13:45 Lunch Break
15:00-17:00 Session 3: MS III
15:00-16:00 Debate: Patients with radiologically isolated demyelinating syndrome should be considered for MS disease modifying therapy
16:00-17:00
Debate: Should disease-modifying therapies be stopped in patients who have developed secondary progressive MS?
17:00-17:15 Coffee Break
17:15-19:00 Session 4: MS IV
17:15-18:00 Debate: Anti B cell or non specific anti B+T therapy
18:10-19:00 Debate: Can we expect long-term clinical improvement through remyelination?

Friday, March 18, 2016
Stroke
Section Heads: Natan Bornstein, Israel & José Manuel Morão Cabral Ferro, Portugal
08:30-10:30 Session 5: STROKE I
08:30-09:30
Debate: Should asymptomatic intracranial aneurysm always be treated? New treatment guidelines
09:30-10:30
Debate: EBM vs. personalized medicine in stroke victims
10:30-10:45 Coffee Break
10:45-12:45 Session 6: STROKE II
10:45-11:55
Debate: Genetic testing for stroke will never be useful
11:55-12:45
Debate: Carotid dissection: Should anticoagulants be used?
12:45-13:45 Lunch Break
15:00-17:00 Session 7: STROKE III
15:00-16:10 Debate: Is the ABCD2 grading useful for clinical management of TIA patients?
16:10-17:00 Debate: Starting anti-coagulants in post-stroke AF patients: How soon?
17:00-17:15 Coffee Break
17:15-19:00 Session 8: STROKE IV
17:15-18:00
Debate: Endovascular therapy: Start with IV tPA or go directly to the catheter lab?
18:10-19:00 Debate: Testing for thrombophilia in cryptogenic stroke in the young: Is it useful?

Friday, March 18, 2016
Dementia
Section Heads: Murat Emre, Turkey & Alexandre Mendonça, Portugal
08:30-10:30 Session 9: DEMENTIA IMAGING
08:30-09:30
Debate: Is amyloid imaging really helpful in diagnosing AD?
09:30-10:30 Debate: Is imaging of tau the preferable marker of cognitive impairment in AD?
10:30-10:45 Coffee Break
10:45-12:45 Session 10: DEMENTIA II
10:45-11:45 Debate: Dementia with Lewy bodies and dementia of PD are the same disorder
11:45-12:45 Debate: Is MCI-PD a useful concept?
12:45-13:45 Lunch Break
15:00-17:00 Session 11: DEMENTIA III
15:00-16:00 Debate: Does traumatic chronic encephalopathy (CTE) exist?
16:00-17:00 Debate: Dementia with Lewy bodies and Parkinson's disease dementia: Part of one continuum or two distinct entities?
17:00-17:15 Coffee Break
17:15-19:00 Session 12: DEMENTIA IV
17:15-18:00 Debate: ALS with frontotemporal deficits and FTD - a spectrum or separate entities
18:10-19:00 Debate: The diagnosis of AD implies immediate revocation of driving license

Friday, March 18, 2016
Headache
Section Heads: Jose Maria Pereira Monteiro, Portugal & Alan Rapoport, USA
08:30-10:30
Session 13: MOLECULES IN HEADACHE AND SLEEP
08:30-09:30
Debate: CGRP antibodies will become the treatment of choice for chronic migraine
09:30-10:30
Debate: Optimal sleep therapy is superior to migraine preventive medications
10:30-10:45 Coffee Break
10:45-12:45 Session 14: HEADACHE TRIALS AND THE USE OF TECHNOLOGY TO TRACK AND DIAGNOSE
10:45-11:45
Debate: Computers can accurately diagnose primary headache disorders as well as most physicians
11:45-12:45
Debate: The use of a placebo is essential in headache trials
12:45-13:45 Lunch Break
15:00-17:00 Session 15: TREATMENT OF CHRONIC HEADACHE
15:00-16:00
Lecture: The history of CGRP discovery and its importance today
16:00-17:00
Debate: Medication over-use is the main causative factor in chronic migraine
17:00-17:15 Coffee Break
17:15-19:00 Session 16: CORTICAL SPREADING DEPRESSION
17:15-18:15
Debate: Migraine starts in the cortex
18:15-19:00 Debate: Electrical stimulation will replace medications for the treatment of cluster headache

Saturday, March 19, 2016
Parkinson's disease & Movement disorders
Section Heads: Joaquim Ferreira, Portugal & Heinz Reichmann, Germany
08:30-10:30 Session 17: PD/MD I
08:30-09:30
Debate: Vaccination against synuclein will be the treatment of choice in PD
09:30-10:30
Debate: Integrative medicine: Microbiomics and nutrition in PD
10:30-10:45 Coffee Break
10:45-12:45 Session 18: PD/MD II
10:45-11:45
Debate: Is the improvement of MAO-B-I clinically relevant?
11:45-12:45
Debate: Duodopa vs. Apomorphine pumps vs. DBS
12:45-13:45 Lunch Break
15:00-17:00 Session 19: PD/MD III
15:00-16:00
Debate: Do COMT inhibitors have a future?
16:00-17:00
Debate: Genetic tests in at risk subjects for PD: Tell or not to tell an imprecise risk?
17:00-17:15 Coffee Break
17:15-18:15 Session 20: PD/MD AND NEUROPATHOLOGY
17:15-18:15
Debate: Does corticobasal degeneration exist as a clinico-pathological entity?

Saturday, March 19, 2016
Epilepsy
Section Heads: Francisco Sales, Portugal & Michael Sperling, USA
08:30-10:30 Session 21: EPIDEMIOLOGY OF EPILEPSY
08:30-09:30
Debate: Carbamazepine is an outmoded drug and should never be used as a first-line treatment
09:30-10:30
Debate: Can we predict with reasonable confidence which patients with idiopathic generalized epilepsy will remit?
10:30-10:45 Coffee Break
10:45-12:45 Session 22: DIAGNOSTIC EVALUATION
10:45-11:45
Debate: Should we regularly check for autoimmune causes in patients with refractory epilepsy who have no other obvious cause?
11:45-12:45
Debate: Can the Wada test be replaced by fMRI and other techniques?
12:45-13:45 Lunch Break
15:00-17:00 Session 23: EPILEPSY TREATMENT
15:00-16:00
Debate: Should combination therapy be used after failure of one or two antiepileptic drugs?
16:00-17:00 Debate: Should responsive neurostimulation be offered preferentially for patients with well localized focus?
17:00-17:15 Coffee Break
17:15-19:00 Session 24: TREATMENT AND CASE STUDIES
17:15-18:10 Debate: Should non-convulsive status epilepticus be treated aggressively?
18:10-19:00 CASE DISCUSSION

Saturday, March 19, 2016
Rehabilitation / Neuromuscular
Rehabilitation Section Heads: Jorge Lains, Portugal & Dafin Muresanu, Romania
08:30-10:30 Session 25: TRAUMATIC BRAIN INJURY (TBI)
10:30-10:45 Coffee Break
10:45-12:45 Session 26: REHABILITATION
10:45-11:45 Debate: Are the present neurorehabilitation methods adequate?
11:45-12:45 Debate: Restorative peripheral neuropathy
12:45-13:45 Lunch Break
15:00-17:00 Session 27: NEUROMUSCULAR I
15:00-16:00 Debate: Sporadic IBM is primarily degenerative
16:00-17:00 Debate: Ischemic myelopathy due to mechanical compression leads to monomelic atrophy (Hirayama disease)
17:00-17:15 Coffee Break
17:15-18:15 Session 28: NEUROMUSCULAR II
17:15-18:15 Debate: CIDP: Steroids vs. IVIg

Sunday, March 20, 2016
Plenary lectures: Beyond the horizon series
Presentation of the CONy "Excellence in Neurology" Award
Awardee: Fernando Tome, Portugal
Close encounter on chromosome 14
Sergiu Blumen, Israel
Beyond the horizon in genetics
Guy Rouleau, Canada
Beyond the horizon in muscle diseases
Valerie Askanas, USA
Beyond the horizon in neuropathology
Lea Grinberg, USA/Brazil
Beyond the horizon in dementia
George Perry, USA
Beyond the horizon in stroke
Lou Caplan, USA
Beyond the horizon in movement disorders: Challenges and unmet needs in PD
Jose Obseo, Spain
Beyond the horizon in Huntington's disease
Cristina Sampaio, USA
Beyond the horizon in epilepsy
Michael Sperling, USA
Beyond the horizon: Redefining neurological diseases through epigenetics
Tiago Fleming Outeiro, Germany
Beyond the horizon: Can neurology solve the free will paradox?
Mark Hallett, USA
Hysteria, simulation and functional disorders: From Charcot to Charcot?
Julien Bogousslavsky, Switzerland